Mipomersen
![Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set](http://data.docslib.org/img/264x/135084d885a0ce0d8ef8f9f83426c79a.webp)
Top View
- The Effect of Mipomersen in the Management of Patients with Familial Hypercholesterolemia: a Systematic Review and Meta-Analysis of Clinical Trials
- Mipomersen (Kynamro) Reference Number: ERX.SPA.171 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log
- Antisense Oligonucleotide, Across Species S
- Kynamro, INN-Mipomersen
- Kynamro® (Mipomersen Sodium) Effective 4/1/2020
- CT-16427 REPATHA REEVAL PIC AVIS3 CT16427.Pdf
- WO 2016/127019 A2 11 August 2016 (11.08.2016) P O P C T
- NVA237 / Glycopyrronium Bromide Multinational, Multi-Database Cohort
- Annual Report 2013
- ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
- UPMC Medicare 2016
- Cell, Gene, & RNA Therapy Landscape
- Study Protocol 1002-048 Amendment 2, 10 February 2017
- 211616Orig1s000
- Bile Acid Sequestrants • Niacin • Fibrates • Mipomersen • Lomitapide • LDL Apheresis Evidence for Treating All FH Patients
- Bempedoic Acid and Inclisiran for Patients with Heterozygous Familial Hypercholesterolemia and for Secondary Prevention of ASCVD: Effectiveness and Value
- Treatment of Hypertriglyceridemia: a Review of Current Options
- Mipomersen (Kynamro) Reference Number: CP.PHAR.284 Effective Date: 10.16 Last Review Date: 02.20 Line of Business: Commercial, Medicaid Revision Log